39 studies found for:    "paroxysmal nocturnal hemoglobinuria"
Show Display Options
Rank Status Study
21 Completed Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Paroxysmal Nocturnal Hemoglobinuria;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Relapsing Chronic Myelogenous Leukemia;   Thrombocytopenia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bryostatin 1;   Biological: sargramostim;   Other: laboratory biomarker analysis;   Other: pharmacological study
22 Active, not recruiting Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Fanconi Anemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: anti-thymocyte globulin
23 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
24 Completed The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Hemoglobinuria, Paroxysmal
Intervention:
25 Completed Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Secondary AML;   Myelodysplastic Syndrome (MDS);   Secondary MDS;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia (JMML);   Paroxysmal Nocturnal Hemoglobinuria (PNH);   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Procedure: Stem Cell Transplantation;   Device: Miltenyi Biotec CliniMACS;   Drug: Systemic chemotherapy and antibodies
26 Completed
Has Results
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Conditions: Sickle Cell Anemia;   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria (PNH);   Pure Red Cell Aplasia
Intervention: Drug: Campath, Chemo and/or TBI Allo SCT
27 Completed Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Leukemia
Intervention: Biological: eculizumab
28 Completed Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Condition: Hemoglobinuria
Intervention:
29 Completed Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
30 Approved for marketing The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
31 Completed Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
32 Completed Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: eculizumab
33 Unknown  Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Condition: Hemoglobinuria, Paroxysmal
Intervention:
34 Active, not recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
35 Unknown  Identifying Characteristics of Bone Marrow Failure Syndromes
Conditions: Bone Marrow Failure Syndromes;   Anemia, Aplastic;   Myelodysplastic Syndromes;   Hemoglobinuria, Paroxysmal;   Red-Cell Aplasia, Pure;   Purpura, Thrombocytopenic;   Leukemia, Lymphocytic
Intervention:
36 Recruiting Natural History of Sickle Cell Disease and Other Hemolytic Disorders
Conditions: Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:
37 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
38 Active, not recruiting Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal
Intervention: Drug: Basiliximab
39 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC

Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page
Indicates status has not been verified in more than two years